2.4.0.81040 - Disclosure - License and Collaboration Agreementstruefalsefalse1false
falsefalseD2013Q2YTDhttp://www.sec.gov/CIK0001274792duration2013-01-01T00:00:002013-06-30T00:00:001true
1mack_LicenseAndCollaborationAgreementsDisclosureAbstractmack_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse| 1falsefalsefalse00falsefalsefalse | xbrli:stringItemTypestringfalse0
2false
2us-gaap_CollaborativeArrangementDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel| 1falsefalsefalse00<div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">4. License and Collaboration Agreements</font></b></p>
<p style="MARGIN: 0in 0in 0pt;"> </p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Sanofi</font></b></p>
<p style="MARGIN: 0in 0in 0pt;"> </p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On September 30, 2009, the Company entered into a license and collaboration agreement with Sanofi for the development and commercialization of a drug candidate being developed by the Company under the name MM-121. The agreement became effective on November 10, 2009 and Sanofi paid the Company a nonrefundable, noncreditable upfront license fee of $60.0 million. During the years ended 2010 and 2011, the Company received a total of $20.0 million in milestone payments associated with dosing the first patients in Phase 2 clinical trials in breast cancer and non-small cell lung cancer. During the first quarter of 2012, the Company received an additional milestone payment of $5.0 million associated with dosing the first patient in a Phase 2 clinical trial in ovarian cancer. The Company is eligible to receive additional future development, regulatory and sales milestone payments as well as future royalty payments depending on the success of MM-121.</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Under the agreement, Sanofi is responsible for all MM-121 development and manufacturing costs. The Company has the right, but not the obligation, to co-promote MM-121 in the United States and to participate in the development of MM-121 through Phase 2 proof of concept trials. Sanofi reimburses the Company for direct costs incurred in development and compensates the Company for its internal development efforts based on a full time equivalent (“FTE”) rate. Also as part of the agreement, the Company was required to manufacture certain quantities of MM-121 and, at Sanofi’s and the Company’s option, may continue to manufacture additional quantities of MM-121 in the future. Sanofi reimburses the Company for direct costs incurred in manufacturing and compensates the Company for its internal manufacturing efforts based on an FTE rate. The Company has satisfied its manufacturing obligations under the agreement as of June 30, 2013.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company applied revenue recognition guidance to determine whether the performance obligations under this collaboration, including the license, the right to future technology, back-up compounds, participation on steering committees, development services and manufacturing services, could be accounted for separately or as a single unit of accounting. The Company determined that its development services performance obligation is considered a separate unit of accounting, as it is set at the Company’s option, has stand-alone value and the FTE rate is considered fair value. Therefore, the Company recognizes cost reimbursements for MM-121 development services as incurred. The Company determined that the license, the right to future technology, back-up compounds, participation on steering committees and manufacturing services performance obligations represented a single unit of accounting. As the Company cannot reasonably estimate its level of effort over the collaboration, the Company recognizes revenue from the upfront payment, milestone payment and manufacturing services payments using the contingency-adjusted performance model over the expected development period, which is currently estimated to be 12 years from the effective date of the agreement. Under this model, when a milestone is earned or manufacturing services are rendered and product is delivered, revenue is immediately recognized on a pro-rata basis in the period the milestone was achieved or product was delivered based on the time elapsed from the effective date of the agreement. Thereafter, the remaining portion is recognized on a straight-line basis over the remaining development period.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">During the three and six months ended June 30, 2012 and 2013, the Company recognized revenue based on the following components of the Sanofi agreement:</font></p>
<p style="MARGIN: 0in 0in 0pt;"> </p>
<table style="text-align:left;WIDTH: 93.34%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="93%">
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="36%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 28.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="28%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three months ended<br />
June 30,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 28.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="28%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Six months ended<br />
June 30,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td></tr>
<tr style="padding:0;">
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.78%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="36%">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(in thousands)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td></tr>
<tr style="padding:0;">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" width="36%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Upfront payment</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,250</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,250</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,500</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,500</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" width="36%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Milestone payments</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">521</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">521</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,933</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,042</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" width="36%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Development services</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9,160</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">14,682</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">17,302</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">26,272</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" width="36%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Manufacturing services and other</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,106</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,999</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,627</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,740</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" width="36%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">12,037</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">18,452</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">23,362</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">32,554</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td></tr></table>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of December 31, 2012 and June 30, 2013, the Company maintained the following assets and liabilities related to the Sanofi agreement:</font></p>
<p style="MARGIN: 0in 0in 0pt;"> </p>
<table style="text-align:left;WIDTH: 96.66%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="96%">
<tr style="padding:0;">
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">(in thousands)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">December 31, 2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">June 30, 2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td></tr>
<tr style="padding:0;">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="68%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accounts receivable, billed</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,577</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,789</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="68%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accounts receivable, unbilled</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7,690</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">12,746</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="68%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Deferred revenue</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">79,913</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">78,060</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"> </p></td></tr>
<tr style="padding:0;">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="498"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="18"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="10"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="83"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="18"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="89"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"></td></tr></table>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">GTC Biotherapeutics, Inc.</font></b></p>
<p style="MARGIN: 0in 0in 0pt;"> </p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In July 2009, the Company entered into a license agreement with GTC Biotherapeutics, Inc. (“GTC”) for the development of MM-093 by GTC. On March 19, 2013, GTC terminated the license agreement. As a result, the Company recognized the remaining $0.6 million of deferred revenue related to this license agreement during the first quarter of 2013.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">PharmaEngine, Inc.</font></b></p>
<p style="MARGIN: 0in 0in 0pt;"> </p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On May 5, 2011, the Company entered into an assignment, sublicense and collaboration agreement with PharmaEngine, Inc. (“PharmaEngine”) under which the Company reacquired rights in Europe and certain countries in Asia to a drug being developed under the name MM-398. In exchange, the Company agreed to pay PharmaEngine a nonrefundable, noncreditable upfront payment of $10.0 million and will be required to make up to an aggregate of $80.0 million in development and regulatory milestone payments and $130.0 million in sales milestone payments upon the achievement of specified development, regulatory and annual net sales milestones. During the first quarter of 2012, the Company paid a milestone of $5.0 million under the collaboration agreement with PharmaEngine in connection with dosing the first patient in a Phase 3 clinical trial of MM-398 in pancreatic cancer. PharmaEngine is also entitled to tiered royalties on net sales of MM-398 in Europe and certain countries in Asia. The Company is responsible for all future development costs of MM-398 except those required specifically for regulatory approval in Taiwan.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">During the three months ended June 30, 2012 and 2013, the Company recognized research and development expenses of $0.3 million and $0.2 million, respectively, and during the six months ended June 30, 2012 and 2013, the Company recognized research and development expenses of $5.6 million and $0.5 million, respectively, related to the agreement with PharmaEngine. These amounts included a $5.0 million milestone payment expensed in the first quarter of 2012.</font></p>
<p style="MARGIN: 0in 0in 0pt;"> </p>
</div>falsefalsefalse | nonnum:textBlockItemTypenaThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-1
-Paragraph 21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
false0
falseLicense and Collaboration AgreementsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.merrimackpharma.com/role/DisclosureLicenseAndCollaborationAgreements12